The use of resazurin as a novel antimicrobial agent against Francisella tularensis

Frontiers in Cellular and Infection Microbiology

Volumn 3, Issue DEC, 2013, Pages

  Schmitt, Deanna M ^a   O'Dee, Dawn M ^b   Cowan, Brianna N ^a   Birch, James W M ^a   Mazzella, Leanne K ^a   Nau, Gerard J ^b   Horzempa, Joseph ^a  

^a WEST LIBERTY UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibacterial; Antibiotic; Francisella; Macrophages; Neisseria; Resazurin; Resorufin; Tularemia

Indexed keywords

ANTIINFECTIVE AGENT; RESAZURIN; ANTIBIOTIC AGENT; OXAZINE DERIVATIVE; RESORUFIN; XANTHENE DERIVATIVE;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL VIABILITY; CONTROLLED STUDY; FRANCISELLA TULARENSIS; HUMAN; HUMAN CELL; LIMIT OF DETECTION; MACROPHAGE; NEISSERIA GONORRHOEAE; NONHUMAN; PATHOGENESIS; PHAGOCYTE; SPECTROPHOTOMETER; BACTERIAL COUNT; BIOTRANSFORMATION; CELL LINE; DRUG EFFECT; EPITHELIUM CELL; FRANCISELLA; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; NEISSERIA; TULAREMIA; DRUG EFFECTS;

ANTIBACTERIAL; ANTIBIOTIC; FRANCISELLA; MACROPHAGES; NEISSERIA; RESAZURIN; RESORUFIN; TULAREMIA;

ANTI-INFECTIVE AGENTS; BIOTRANSFORMATION; CELL LINE; COLONY COUNT, MICROBIAL; EPITHELIAL CELLS; FRANCISELLA TULARENSIS; HUMANS; MACROPHAGES; MICROBIAL VIABILITY; OXAZINES; XANTHENES;

EID: 84897918849     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2013.00093     Document Type: Article

References (37)

1. Ahmed, S. A., Gogal, R. M. Jr., and Walsh, J. E. (1994). A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Methods 170, 211-224. doi: 10.1016/0022-1759(94)90396-4.
2. Barry, E. M., Cole, L. E., and Santiago, A. E. (2009). Vaccines against tularemia. Hum. Vaccin. 5, 832-838. Available online at: https://www.landesbioscience.com/journals/vaccines/article/10297/ or https://www.landesbioscience.com/journals/vaccines/BarryHV5-12.pdf.
3. Bassett, I. M., Lun, S., Bishai, W. R., Guo, H., Kirman, J. R., Altaf, M., et al. (2013). Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen. J. Microbiol. 51, 651-658. doi: 10.1007/s12275-013-3099-4.
4. Bassetti, M., Merelli, M., Temperoni, C., and Astilean, A. (2013). New antibiotics for bad bugs: where are we? Ann. Clin. Microbiol. Antimicrob. 12, 22. doi: 10.1186/1476-0711-12-22.
5. Bauer, J., Siala, W., Tulkens, P. M., and Van Bambeke, F. (2013). A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 57, 2726-2737. doi: 10.1128/AAC.00181-13.
6. Carlson, P. E. Jr., Carroll, J. A., O'Dee, D. M., and Nau, G. J. (2007). Modulation of virulence factors in Francisella tularensis determines human macrophage responses. Microb. Pathog. 42, 204-214. doi: 10.1016/j.micpath.2007.02.001.
7. Carlson, P. E. Jr., Horzempa, J., O'Dee, D. M., Robinson, C. M., Neophytou, P., Labrinidis, A., et al. (2009). Global transcriptional response to spermine, a component of the intramacrophage environment, reveals regulation of Francisella gene expression through insertion sequence elements. J. Bacteriol. 191, 6855-6864. doi: 10.1128/JB.00995-09.
8. Conlan, J. W., and Oyston, P. C. (2007). Vaccines against Francisella tularensis. Ann. N.Y. Acad. Sci. 1105, 325-350. doi: 10.1196/annals.1409.012.
9. Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., et al. (2001). Tularemia as a biological weapon: medical and public health management. JAMA 285, 2763-2773. doi: 10.1001/jama.285.21.2763.
10. Elkins, K. L., Cowley, S. C., and Bosio, C. M. (2007). Innate and adaptive immunity to Francisella. Ann. N.Y. Acad. Sci. 1105, 284-324. doi: 10.1196/annals.1409.014.
11. Horzempa, J., Carlson, P. E. Jr., O'Dee, D. M., Shanks, R. M., and Nau, G. J. (2008a). Global transcriptional response to mammalian temperature provides new insight into Francisella tularensis pathogenesis. BMC Microbiol. 8:172. doi: 10.1186/1471-2180-8-172.
12. Horzempa, J., Tarwacki, D. M., Carlson, P. E. Jr., Robinson, C. M., and Nau, G. J. (2008b). Characterization and application of a glucose-repressible promoter in Francisella tularensis. Appl. Environ. Microbiol. 74, 2161-2170. doi: 10.1128/AEM.02360-07.
13. Horzempa, J., O'Dee, D. M., Shanks, R. M., and Nau, G. J. (2010). Francisella tularensis DeltapyrF mutants show that replication in nonmacrophages is sufficient for pathogenesis in vivo. Infect. Immun. 78, 2607-2619. doi: 10.1128/IAI.00134-10.
14. Horzempa, J., O'Dee, D. M., Stolz, D. B., Franks, J. M., Clay, D., and Nau, G. J. (2011). Invasion of erythrocytes by Francisella tularensis. J. Infect. Dis. 204, 51-59. doi: 10.1093/infdis/jir221.
15. Lall, N., Henley-Smith, C. J., De Canha, M. N., Oosthuizen, C. B., and Berrington, D. (2013). Viability reagent, prestoblue, in comparison with other available reagents, utilized in cytotoxicity and antimicrobial assays. Int. J. Microbiol. 2013:420601. doi: 10.1155/2013/420601.
16. Lewis, K. (2013). Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371-387. doi: 10.1038/nrd3975.
17. Lutty, G. A. (1978). The acute intravenous toxicity of biological stains, dyes, and other fluorescent substances. Toxicol. Appl. Pharmacol. 44, 225-249. doi: 10.1016/0041-008X(78)90185-0.
18. McKenney, E. S., Sargent, M., Khan, H., Uh, E., Jackson, E. R., San Jose, G., et al. (2012). Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy. PLoS ONE 7:e38167. doi: 10.1371/journal.pone.0038167.
19. McLendon, M. K., Apicella, M. A., and Allen, L. A. (2006). Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare. Annu. Rev. Microbiol. 60, 167-185. doi: 10.1146/annurev.micro.60.080805.142126.
20. Mendoza-Aguilar, M., Almaguer-Villagran, L., Jimenez-Arellanes, A., Arce-Paredes, P., Cid-Gutierrez, J. L., and Rojas-Espinosa, O. (2012). The use of the microplate alamar blue assay (MABA) to assess the susceptibility of Mycobacterium lepraemurium to anti-leprosy and other drugs. J. Infect. Chemother. 18, 652-661. doi: 10.1007/s10156-012-0387-6.
21. Nigrovic, L. E., and Wingerter, S. L. (2008). Tularemia. Infect. Dis. Clin. North Am. 22, 489-504, ix. doi: 10.1016/j.idc.2008.03.004.
22. O'Brien, J., Wilson, I., Orton, T., and Pognan, F. (2000). Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267, 5421-5426. doi: 10.1046/j.1432-1327.2000.01606.x.
23. Oyston, P. C. (2008). Francisella tularensis: unravelling the secrets of an intracellular pathogen. J. Med. Microbiol. 57, 921-930. doi: 10.1099/jmm.0.2008/000653-0.
24. Oyston, P. C. (2009). Francisella tularensis vaccines. Vaccine 27(Suppl. 4), D48-D51. doi: 10.1016/j.vaccine.2009.07.090.
25. Oyston, P. C., Sjostedt, A., and Titball, R. W. (2004). Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2, 967-978. doi: 10.1038/nrmicro1045.
26. Page, B., Page, M., and Noel, C. (1993). A new fluorometric assay for cytotoxicity measurements in-vitro. Int. J. Oncol. 3, 473-476.
27. Post, D. M., Phillips, N. J., Shao, J. Q., Entz, D. D., Gibson, B. W., and Apicella, M. A. (2002). Intracellular survival of Neisseria gonorrhoeae in male urethral epithelial cells: importance of a hexaacyl lipid A. Infect. Immun. 70, 909-920. doi: 10.1128/IAI.70.2.909-920.2002.
28. Robinson, C. M., Jung, J. Y., and Nau, G. J. (2012). Interferon-gamma, tumor necrosis factor, and interleukin-18 cooperate to control growth of Mycobacterium tuberculosis in human macrophages. Cytokine 60, 233-241. doi: 10.1016/j.cyto.2012.06.012.
29. Robinson, C. M., and Nau, G. J. (2008). Interleukin-12 and interleukin-27 regulate macrophage control of Mycobacterium tuberculosis. J. Infect. Dis. 198, 359-366. doi: 10.1086/589774.
30. Robinson, C. M., O'Dee, D., Hamilton, T., and Nau, G. J. (2010). Cytokines involved in interferon-gamma production by human macrophages. J. Innate Immun. 2, 56-65. doi: 10.1159/000247156.
31. Russo, B. C., Horzempa, J., O'Dee, D. M., Schmitt, D. M., Brown, M. J., Carlson, P. E., et al. (2011). A Francisella tularensis locus required for spermine responsiveness is necessary for virulence. Infect. Immun. 79, 3665-3676. doi: 10.1128/IAI.00135-11.
32. Schmitt, D. M., O'Dee, D. M., Horzempa, J., Carlson, P. E. Jr., Russo, B. C., Bales, J. M., et al. (2012). A Francisella tularensis live vaccine strain that improves stimulation of antigen-presenting cells does not enhance vaccine efficacy. PLoS ONE 7:e31172. doi: 10.1371/journal.pone.0031172.
33. Sjostedt, A. (2007). Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. N.Y. Acad. Sci. 1105, 1-29. doi: 10.1196/annals.1409.009.
34. Small, P. L., Isberg, R. R., and Falkow, S. (1987). Comparison of the ability of enteroinvasive Escherichia coli, Salmonella typhimurium, Yersinia pseudotuberculosis, and Yersinia enterocolitica to enter and replicate within HEp-2 cells. Infect. Immun. 55, 1674-1679.
35. Tachado, S. D., Zhang, J., Zhu, J., Patel, N., Cushion, M., and Koziel, H. (2007). Pneumocystis-mediated IL-8 release by macrophages requires coexpression of mannose receptors and TLR2. J. Leukoc. Biol. 81, 205-211. doi: 10.1189/jlb.1005580.
36. Thomas, L. D., and Schaffner, W. (2010). Tularemia pneumonia. Infect. Dis. Clin. North Am. 24, 43-55. doi: 10.1016/j.idc.2009.10.012.
37. Wainwright, M. (2001). Acridine-a neglected antibacterial chromophore. J. Antimicrob. Chemother. 47, 1-13. doi: 10.1093/jac/47.1.1.